Alnylam Pharmaceuticals (ALNY) PT Lowered to $125 at BMO Capital; Onpattro U.S. Approval Lacks Benefit From Cardiac Data

BMO Capital analyst Do Kim lowered the price target on Alnylam Pharmaceuticals (NASDAQ: ALNY) to $125.00 (from $127.00) while maintaining an Outperform rating saying the Onpattro U.S. approval lacks benefit from cardiac data.

"We believe the label's lack of cardiac data will pressure the shares in the near term, with unlikely relief from the Tafamidis ESC presentation on August 27," Kim said. "We expect a better setup after ESC and ahead of interim Givosiran data in September 2018."

You May Also Be Interested In

• Fiserv (FISV) PT Lowered to $60 at Freedom Broker
• GMR Airports Infrastructure (GMRI:IN) PT Raised to INR99 at ICICI Securities
• Honasa Consumer Ltd (HONASA:IN) PT Raised to INR720 at ICICI Securities